EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma

Xu, Zihai; Zhang, L.; Gao, Baofeng; Wan, Yi; Zhang, X. H.; Chen, B.; Wang, Y. T.; Sun, Nao; Fu, Yu

doi:10.1007/s12094-014-1195-5

Cited by 24 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epigenetic silencing resulting in the inactivation of tumor suppressor genes is believed to be the underlying mechanism through which overexpression of EZH2 results in the transcriptional repression of tumor suppressor genes. EZH2 overexpression Novel Biomarkers of Prognosis in ACC has been associated with aggressive carcinoma of the breast, colon, prostate, kidney, and endometrium and sarcomas and lymphomas [62][63][64][65][66][67]. Given the increasing evidence of the oncogenic role of EZH2 overexpression in other tumors, this seemed to be a logical marker to pursue.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Validation of Overexpressed Genes Identified by Global Expression Microarrays in Adrenocortical Carcinoma Reveals Potential Predictive and Prognostic Biomarkers

Pang

Glover

et al. 2015

The Oncologist

View full text Add to dashboard Cite

Background. Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. The aim of this study was to identify novel protein signatures that would predict clinical outcomes in a large cohort of patients with ACC based on data from previous gene expression microarray studies. Materials and Methods. A tissue microarray was generated from the paraffin tissue blocks of 61 patients with clinical outcomes data. Selected protein biomarkers based on previous gene expression microarray profiling studies were selected, and immunohistochemistry staining was performed. Staining patterns were correlated with clinical outcomes, and a multivariate analysis was undertaken to identify potential biomarkers of prognosis. Results. Median overall survival was 45 months, with a 5-year overall survival rate of 44%. Median disease-free survival was 58 months, with a 5-year disease-free survival rate of 44%.The

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Validation of Overexpressed Genes Identified by Global Expression Microarrays in Adrenocortical Carcinoma Reveals Potential Predictive and Prognostic Biomarkers

Pang

Glover

et al. 2015

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Inhibition of EZH2 function by small interfering RNA causes reduction of vascular endothelial growth factor (VEGF) level and cell proliferation, as well as induction of apoptosis in 786-O ccRCC cells. On the contrary, EZH2 over-expression reverses these effects on VEGF level, cell proliferation, and apoptosis in vitro and in vivo [83]. …”

Section: Oncogenic Roles Of Ezh2 In Cancer Progressionmentioning

confidence: 99%

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

Yan

Lin

Liao

et al. 2017

IJMS

View full text Add to dashboard Cite

Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes tri-methylation of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic machinery. EZH2 functions as a double-facet molecule in regulation of gene expression via repression or activation mechanisms, depending on the different cellular contexts. EZH2 interacts with both histone and non-histone proteins to modulate diverse physiological functions including cancer progression and malignancy. In this review article, we focused on the updated information regarding microRNAs (miRNAs) and long non coding RNAs (lncRNAs) in regulation of EZH2, the oncogenic and tumor suppressive roles of EZH2 in cancer progression and malignancy, as well as current pre-clinical and clinical trials of EZH2 inhibitors.

show abstract

“…There is increasing evidence that EZH2 promotes angiogenesis in clear renal cell carcinoma, inflammatory breast cancer, nasopharyngeal carcinoma (NPC) and glioblastomas (GBM) [13, 40, 57]. High expression levels of EZH2 and VEGF correlate with TMN stage and distant metastasis in advanced clear renal cell carcinoma [13].…”

Section: The Functional Role Of Ezh2mentioning

confidence: 99%

“…High expression levels of EZH2 and VEGF correlate with TMN stage and distant metastasis in advanced clear renal cell carcinoma [13]. In nasopharyngeal carcinoma (NPC), elevated EZH2 levels were associated with an aggressive phenotype with poor prognosis and enhanced microvessel density [18].…”

Section: The Functional Role Of Ezh2mentioning

confidence: 99%

See 1 more Smart Citation

Functional and therapeutic significance of EZH2 in urological cancers

Liu

2017

Oncotarget

View full text Add to dashboard Cite

The enhancer of zeste homolog 2 (EZH2) is a core subunit of the polycomb repressor complex 2 (PRC2), which is overexpressed in numerous cancers and mutated in several others. Notably, EZH2 acts not only a critical epigenetic repressor through its role in histone methylation, it is also an activator of gene expression, acting through multiple signaling pathways in distinct cancer types. Increasing evidence suggests that EZH2 is an oncogene and is central to initiation, growth and progression of urological cancers. In this review, we highlight the critical role of EZH2 as a master regulator of tumorigenesis in the prostate, bladder and the kidney through epigenetic control of transcription as well as a modulation of various critical signaling pathways. We also discuss the promise and challenges for EZH2 inhibitors as future anticancer therapeutics, some of which are currently in clinical trials.

show abstract

EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma

Cited by 24 publications

References 19 publications

Immunohistochemical Validation of Overexpressed Genes Identified by Global Expression Microarrays in Adrenocortical Carcinoma Reveals Potential Predictive and Prognostic Biomarkers

Immunohistochemical Validation of Overexpressed Genes Identified by Global Expression Microarrays in Adrenocortical Carcinoma Reveals Potential Predictive and Prognostic Biomarkers

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

Functional and therapeutic significance of EZH2 in urological cancers

Contact Info

Product

Resources

About